ennshapkabg
 

Celebration 67 years The Stephan Angeloff Institute of Microbiology

 

Microbiologia Balkanica 2013 - 8th Balkan Congress of Microbiology, Veliko Tarnovo, Bulgaria

 

Pitagor 2012 awarded to Assoc. Prof. Andrey Tchorbanov from The Stephan Angeloff Institute of Microbiology

 

Meeting of the President of BAS prof. Nikola Sabotinov with Dr. Mark Jouan from RIIP

 

Official ceremony of Academic degrees diploma awards

 

Pitagor 2011 awarded to two researchers from The Stephan Angeloff Institute of Microbiology

 

 

Закон за развитие на академичния състав в Република България

 

 

Правилник за прилагане на Закона за развитието на академичния състав в Република България

 

 

Процедури по закона за развитие на академичния състав в Република България

 

 

science daily

 

 

sciencenews

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bulgarian Academy of Sciences

 

Ministry of Education and Science

 

National Science Fund

 

Central Library of BAS

 

Union of Scientists in Bulgaria

 

European
Comission: Horizon 2020

Institut Pasteur

 

DKFZ

 

FEMS

 

PubMed Cenral

 

EURAXESS

 

Scopus

 

Google

 

 

mail

 

 

 

 

 

 

 

DEPARTMENT OF IMMUNOLOGY

 

 

Head: Professor Nina Ivanovska, DSc

 

Tel: +359 2 979 31 95

 

е-mail: nina@microbio.bas.bg

 

Staff


thumb1

 

LABORATORY of Infectious Immunology and Inflammation

 

Head: Professor Nina Ivanovska, DSc

 

e-mail: nina@microbio.bas.bg

 

 

Laboratory of Experimental Immunology

 

Head: Associate Professor Andrey Tchorbanov, PhD

 

e-mail: tchorban@microbio.bas.bg

 

LABORATORY of Experimental Immunotherapy

Head: Associate Professor Anastas Pashov, PhD

е-mail: a_pashov@microbio.bas.bg

 

 

Most Important results

 

 

  • Pathological DNA-specific B and T cells in SLE are logical targets for a selected therapeutic intervention. We have constructed chimeric molecules by coupling of different epitope-specific peptides to monoclonal antibodies. Our data show that it is possible to suppress selectively the activity of targeted autoreactive B and T-lymphocytes and to change the natural course of an autoimmune disease in mouse models or humanized transfer models of lupus by administering chimeric molecules that cross-link the inhibitory receptors with the immunoglobulin B cell receptor.

  • Introduction of DNA vaccines is a new approach to vaccination. Such a hybrid DNA molecules were constructed by us, encoding a T and B cell epitope-containing influenza hemagglutinin peptide and a scFv antibody fragment binding to mouse complement receptors I and II or human FcγRI. A single or double immunization with a plasmid containing the described construct induced a strong anti-influenza cytotoxic response lasting for more than six months and a weak antibody response.

  • We have worked on new therapeutic strategies in sepsis as there is an urgent unmet medical need for new treatments for this disease. Our therapeutic approach consists of the development and use of improved immunoglobulins “next generation” immunoglobulin preparations with enhanced
    anti-inflammatory activity.

  • We have characterised the role of properdin, a positive regulator of the complement system, in experimental models of sepsis and arthritis. Our studies demonstrate that properdin deficiency attenuates the symptoms of Zy-induced shock and exacerbates LPS-induced shock. It uncovers, for the first time, a relationship between properdin and macrophage as well as platelet functions in models of nonspetic shock. Our data showed that properdin, appeared to have a protective role in the processes of joint erosion which suggest that alternative pathway of complement might be actively involved in the chronic inflammation in rheumatoid arthritis. Another strand of our work characterises the antiinflammatory action of tyrosine kinase inhibitors in models of sepsis, particularly via STAT signaling

  • We have contributed to osteoimmunology research by determining on a molecular level the manner in which inflammation impairs bone formation and the extent to which signalling pathways are altered as a consequence. The investigations are carried out in patients with osteoarthritis and in a murine model of collagenase-induced osteoarthritis. Current work is focused on application of glucosamine as a potential antiarthritic agent. The mechanism of its action is studied with regard to neutrophils, key cytokines and chemokines and also RANKL signaling in relation to events leading to osteoclastogenesis.